Clinical management of androgen excess and defect in women

References

• Sciarra F, Campolo F, Franceschini E, et al. Gender-specific impact of sex hormones on the immune system. IJMS. 2023;24(7):6302.
   Google Scholar
• Matsumoto T, Sakari M, Okada M, et al. The androgen receptor in health and disease. Annu Rev Physiol. 2013;75(1):201–224.
   PubMedGoogle Scholar
• Rosato E, Sciarra F, Anastasiadou E, et al. Revisiting the physiological role of androgens in women. Expert Rev Endocrinol Metab. 2022;17(6):547–561.
   PubMed Web of Science ®Google Scholar
• Chang C, Lee SO, Wang R-S, et al. Androgen receptor (AR) physiological roles in male and female reproductive systems: lessons learned from AR-knockout mice lacking AR in selective cells. Biol Reprod. 2013;89(1):21.
   PubMed Web of Science ®Google Scholar
• Abbott DH. Neuronal androgen receptor: molecular gateway to polycystic ovary syndrome? Proc Natl Acad Sci U S A. 2017;114(16):4045–4047. doi: 10.1073/pnas.1703436114
   PubMed Web of Science ®Google Scholar
• Puttabyatappa M, Padmanabhan V. Ovarian and Extra-ovarian Mediators in the development of polycystic ovary syndrome. J Mol Endocrinol. 2018;61(4):R161–r184. doi: 10.1530/JME-18-0079
   PubMed Web of Science ®Google Scholar
• Wierman ME, Arlt W, Basson R, et al. Androgen therapy in women: a reappraisal: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2014;99(10):3489–3510.
   PubMed Web of Science ®Google Scholar
• Scavello I, Maseroli E, Di Stasi V, et al. Sexual Health in Menopause. Medicina (Kaunas). 2019;55(9):559.
   PubMed Web of Science ®Google Scholar
• Nappi RE, Tiranini L, Martini E, et al. Medical Treatment of Female Sexual Dysfunction. Urol Clin North Am. 2022;49(2):299–307.
   PubMed Web of Science ®Google Scholar
• Wåhlin-Jacobsen S, Pedersen AT, Kristensen E, et al. Is there a correlation between androgens and sexual desire in women? J Sex Med. 2015;12(2):358–373.
   PubMed Web of Science ®Google Scholar
• Randolph JF Jr., Zheng H, Avis NE, et al. Masturbation frequency and sexual function domains are associated with serum reproductive hormone levels across the menopausal transition. J Clin Endocrinol Metab. 2015;100(1):258–266.
   PubMed Web of Science ®Google Scholar
• Sharma A, Welt CK. Practical approach to hyperandrogenism in women. Med Clin North Am. 2021;105(6):1099–1116. doi: 10.1016/j.mcna.2021.06.008
   PubMed Web of Science ®Google Scholar
• Lee AT, Zane LT. Dermatologic manifestations of polycystic ovary syndrome. Am J Clin Dermatol. 2007;8(4):201–219. doi: 10.2165/00128071-200708040-00003
   PubMed Web of Science ®Google Scholar
• Teede HJ, Misso ML, Costello MF, et al. Recommendations from the international evidence-based guideline for the assessment and management of polycystic ovary syndrome. Fertil Steril. 2018;110(3):364–379.
   PubMed Web of Science ®Google Scholar
• Carmina E, Dreno B, Lucky WA, et al. Female Adult Acne and Androgen Excess: A Report From the Multidisciplinary Androgen Excess and PCOS Committee. J Endocr Soc. 2022;6(3):bvac003.
   PubMed Web of Science ®Google Scholar
• Doshi A, Zaheer A, Stiller MJ. A comparison of current acne grading systems and proposal of a novel system. Int J Dermatol. 1997;36(6):416–418. doi: 10.1046/j.1365-4362.1997.00099.x
   PubMed Web of Science ®Google Scholar
• Patel K, Nole KB, Fleischer A Jr. Acne vulgaris: the majority of patients do not achieve success According to FDA guidance. J Drugs Dermatol. 2021;20(6):648–651. doi: 10.36849/JDD.2021.5727
   PubMed Web of Science ®Google Scholar
• Ferriman D, Gallwey JD. Clinical assessment of body hair growth in women. J Clin Endocrinol Metab. 1961;21(11):1440–1447. doi: 10.1210/jcem-21-11-1440
   PubMed Web of Science ®Google Scholar
• Witchel SF, Oberfield SE, Peña AS. Polycystic ovary syndrome: pathophysiology, presentation, and treatment with emphasis on adolescent girls. J Endocr Soc. 2019;3(8):1545–1573. doi: 10.1210/js.2019-00078
   PubMed Web of Science ®Google Scholar
• Lolli F, Pallotti F, Rossi A, et al. Androgenetic alopecia: a review. Endocrine. 2017;57(1):9–17.
   PubMed Web of Science ®Google Scholar
• Ludwig E. Classification of the types of androgenetic alopecia (common baldness) occurring in the female sex. Br J Dermatol. 1977;97(3):247–254. doi: 10.1111/j.1365-2133.1977.tb15179.x
   PubMed Web of Science ®Google Scholar
• Iannone M, Dima AP, Sciarra F, et al. Development and validation of a liquid chromatography–tandem mass spectrometry method for the simultaneous analysis of androgens, estrogens, glucocorticoids and progestagens in human serum. Biomed Chromatogr. 2022;36(5):e5344.
   PubMed Web of Science ®Google Scholar
• Rothman MS, Carlson NE, Xu M, et al. Reexamination of testosterone, dihydrotestosterone, estradiol and estrone levels across the menstrual cycle and in postmenopausal women measured by liquid chromatography–tandem mass spectrometry. Steroids. 2011;76(1–2):177–182.
   PubMed Web of Science ®Google Scholar
• Sadeghi HM, Adeli I, Calina D, et al. Polycystic ovary syndrome: a Comprehensive review of pathogenesis, management, and drug repurposing. IJMS. 2022;23(2):583.
   Google Scholar
• Joham AE, Norman RJ, Stener-Victorin E, et al. Polycystic ovary syndrome. Lancet Diabetes Endocrinol. 2022;10(9):668–680.
   PubMed Web of Science ®Google Scholar
• Azziz R, Sanchez LA, Knochenhauer ES, et al. Androgen excess in women: experience with over 1000 consecutive patients. J Clin Endocrinol Metab. 2004;89(2):453–462.
   PubMed Web of Science ®Google Scholar
• Ehrmann DA. Polycystic ovary syndrome. N Engl J Med. 2005;352(12):1223–1236. doi: 10.1056/NEJMra041536
   PubMed Web of Science ®Google Scholar
• Franks S. Polycystic ovary syndrome. N Engl J Med. 1995;333(13):853–861. doi: 10.1056/NEJM199509283331307
   PubMed Web of Science ®Google Scholar
• Dumesic DA, Oberfield SE, Stener-Victorin E, et al. Scientific statement on the diagnostic criteria, epidemiology, pathophysiology, and molecular genetics of polycystic ovary syndrome. Endocr Rev. 2015;36(5):487–525.
   PubMed Web of Science ®Google Scholar
• Teede HJ, Tay CT, Laven JJE, et al. Recommendations from the 2023 international evidence-based guideline for the assessment and management of polycystic ovary syndrome. Eur J Endocrinol. 2023;189(2):G43–g64.
   PubMed Web of Science ®Google Scholar
• Chen W, Pang Y. Metabolic syndrome and PCOS: Pathogenesis and the role of metabolites. Metabolites. 2021;11(12):869. doi: 10.3390/metabo11120869
   PubMed Web of Science ®Google Scholar
• Gur EB, Karadeniz M, Turan GA. Fetal programming of polycystic ovary syndrome. World J Diabetes. 2015;6(7):936–942. doi: 10.4239/wjd.v6.i7.936
   PubMed Web of Science ®Google Scholar
• Franks S, McCarthy MI, Hardy K. Development of polycystic ovary syndrome: involvement of genetic and environmental factors. Int J Androl. 2006;29(1):278–285. discussion 286-90. doi: 10.1111/j.1365-2605.2005.00623.x
   PubMedGoogle Scholar
• Guo R, Zheng Y, Yang J, et al. Association of TNF-alpha, IL-6 and IL-1beta gene polymorphisms with polycystic ovary syndrome: a meta-analysis. BMC Genet. 2015;16(1):5.
   PubMedGoogle Scholar
• Zhang TT, Yuan L, Yang Y-M, et al. The -675 4G/5G polymorphism in the PAI-1 gene may not contribute to the risk of PCOS. Eur Rev Med Pharmacol Sci. 2014;18(16):2326–2331.
   PubMed Web of Science ®Google Scholar
• M TM, F BH, A RA-S. INSR gene variation is associated with decreased insulin sensitivity in Iraqi women with PCOs. Iran J Reprod Med. 2014;12(7):499–506.
   PubMedGoogle Scholar
• Ramezani Tehrani F, Daneshpour M, Hashemi S, et al. Relationship between polymorphism of insulin receptor gene, and adiponectin gene with PCOS. Iran J Reprod Med. 2013;11(3):185–194.
   PubMedGoogle Scholar
• Diamanti-Kandarakis E, Alexandraki K, Bergiele A, et al. Presence of metabolic risk factors in non-obese PCOS sisters: evidence of heritability of insulin resistance. J Endocrinol Invest. 2004;27(10):931–936.
   PubMed Web of Science ®Google Scholar
• de Melo AS, Dias SV, Cavalli RDC, et al. Pathogenesis of polycystic ovary syndrome: multifactorial assessment from the foetal stage to menopause. Reproduction. 2015;150(1):R11–24.
   PubMed Web of Science ®Google Scholar
• Rosenfield RL, Ehrmann DA. The pathogenesis of polycystic ovary syndrome (PCOS): the hypothesis of PCOS as functional ovarian hyperandrogenism Revisited. Endocr Rev. 2016;37(5):467–520. doi: 10.1210/er.2015-1104
   PubMed Web of Science ®Google Scholar
• Smith JT, Cunningham MJ, Rissman EF, et al. Regulation of Kiss1 gene expression in the brain of the female mouse. Endocrinology. 2005;146(9):3686–3692.
   PubMed Web of Science ®Google Scholar
• Osuka S, Iwase A, Nakahara T, et al. Kisspeptin in the hypothalamus of 2 rat models of polycystic ovary syndrome. Endocrinology. 2017;158(2):367–377.
   PubMed Web of Science ®Google Scholar
• Coutinho EA, Kauffman AS. The role of the brain in the pathogenesis and physiology of polycystic ovary syndrome (PCOS). Med Sci (Basel). 2019;7(8):78. doi: 10.3390/medsci7080084
   PubMedGoogle Scholar
• Katulski K, Podfigurna A, Czyzyk A, et al. Kisspeptin and LH pulsatile temporal coupling in PCOS patients. Endocrine. 2018;61(1):149–157.
   PubMed Web of Science ®Google Scholar
• Wang T, Han S, Tian W, et al. Effects of kisspeptin on pathogenesis and energy metabolism in polycystic ovarian syndrome (PCOS). Gynecol Endocrinol. 2019;35(9):807–810.
   PubMed Web of Science ®Google Scholar
• Chen B, Xu P, Wang J, et al. The role of MiRNA in polycystic ovary syndrome (PCOS). Gene. Gene. 2019;706:91–96. doi: 10.1016/j.gene.2019.04.082
   PubMed Web of Science ®Google Scholar
• Concha CF, Sir P T, Recabarren SE, et al. [Epigenetics of polycystic ovary syndrome]. Rev Med Chil. 2017;145(7):907–915.
   PubMed Web of Science ®Google Scholar
• Cassar S, Misso ML, Hopkins WG, et al. Insulin resistance in polycystic ovary syndrome: a systematic review and meta-analysis of euglycaemic–hyperinsulinaemic clamp studies. Hum Reprod. 2016;31(11):2619–2631.
   PubMed Web of Science ®Google Scholar
• Ciampelli M, Fulghesu AM, Cucinelli F, et al. Impact of insulin and body mass index on metabolic and endocrine variables in polycystic ovary syndrome. Metabolism. 1999;48(2):167–172.
   PubMed Web of Science ®Google Scholar
• Fauser BC, Tarlatzis BC, Rebar RW, et al. Consensus on women’s health aspects of polycystic ovary syndrome (PCOS): the Amsterdam ESHRE/ASRM-Sponsored 3rd PCOS consensus Workshop group. Fertil Steril. 2012;97(1):28–38.e25.
   PubMed Web of Science ®Google Scholar
• Genazzani AD, Ricchieri F, Lanzoni C. Use of metformin in the treatment of polycystic ovary syndrome. Womens Health. 2010;6(4):577–593. doi: 10.2217/WHE.10.43
   Google Scholar
• Quinkler M, Sinha B, Tomlinson JW, et al. Androgen generation in adipose tissue in women with simple obesity – a site-specific role for 17β-hydroxysteroid dehydrogenase type 5. J Endocrinol. 2004;183(2):331–342.
   PubMed Web of Science ®Google Scholar
• Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod. 2004;19(1):41–47. doi: 10.1093/humrep/deh098
   PubMed Web of Science ®Google Scholar
• Goodman NF, Cobin RH, Futterweit W, et al. American association of clinical endocrinologists, American college of endocrinology, and androgen excess and pcos society disease state clinical review: guide to the best practices in the evaluation and treatment of polycystic ovary syndrome–part 1. Endocr Pract. 2015;21(11):1291–1300.
   PubMed Web of Science ®Google Scholar
• Balen AH, Laven JSE, Tan S-L, et al. Ultrasound assessment of the polycystic ovary: international consensus definitions. Hum Reprod Update. 2003;9(6):505–514.
   PubMed Web of Science ®Google Scholar
• Dewailly D, Lujan ME, Carmina E, et al. Definition and significance of polycystic ovarian morphology: a task force report from the androgen excess and polycystic ovary syndrome Society. Hum Reprod Update. 2014;20(3):334–352.
   PubMed Web of Science ®Google Scholar
• Rudnicka E, Kunicki M, Calik-Ksepka A, et al. Anti-Müllerian hormone in pathogenesis, diagnostic and treatment of PCOS. Int J Mol Sci. 2021;22(22):12507.
   PubMed Web of Science ®Google Scholar
• DiVall S, Merjaneh L. Adolescent Polycystic Ovary Syndrome: An Update. Pediatr Ann. 2019;48(8):e304–e310. doi: 10.3928/19382359-20190729-01
   PubMed Web of Science ®Google Scholar
• Rosenfield RL. Clinical review: Adolescent anovulation: maturational mechanisms and implications. J Clin Endocrinol Metab. 2013;98(9):3572–3583. doi: 10.1210/jc.2013-1770
   PubMed Web of Science ®Google Scholar
• Witchel SF, Oberfield S, Rosenfield RL, et al. The diagnosis of polycystic ovary syndrome during adolescence. Horm Res Paediatr. 2015;83(6):376–389.
   Web of Science ®Google Scholar
• Carmina E, Oberfield SE, Lobo RA. The diagnosis of polycystic ovary syndrome in adolescents. Am J Obstet Gynecol. 2010;203(3):201.e1–5. doi: 10.1016/j.ajog.2010.03.008
   PubMed Web of Science ®Google Scholar
• Rosenfield RL. The polycystic ovary morphology-polycystic ovary syndrome spectrum. J Pediatr Adolesc Gynecol. 2015;28(6):412–419. doi: 10.1016/j.jpag.2014.07.016
   PubMed Web of Science ®Google Scholar
• Vryonidou A, Paschou SA, Muscogiuri G, et al. Mechanisms in endocrinology: metabolic syndrome through the female life cycle. Eur J Endocrinol. 2015;173(5):R153–63.
   PubMed Web of Science ®Google Scholar
• Orio F, Muscogiuri G, Ascione A, et al. Effects of physical exercise on the female reproductive system. Minerva Endocrinol. 2013;38(3):305–319.
   PubMed Web of Science ®Google Scholar
• Barrea L, Frias-Toral E, Verde L, et al. PCOS and nutritional approaches: differences between lean and obese phenotype. Metabol Open. 2021;12:100123. doi: 10.1016/j.metop.2021.100123
   PubMedGoogle Scholar
• Moran LJ, Hutchison SK, Norman RJ, et al. Lifestyle changes in women with polycystic ovary syndrome. Cochrane Database Syst Rev. 2011 Feb 16;(2):Cd007506.
   Web of Science ®Google Scholar
• Toosy S, Sodi R, Pappachan JM. Lean polycystic ovary syndrome (PCOS): an evidence-based practical approach. J Diabetes Metab Disord. 2018;17(2):277–285. doi: 10.1007/s40200-018-0371-5
   PubMed Web of Science ®Google Scholar
• Morgante G, Cappelli V, Troìa L, et al. Evaluation of different antiandrogenic progestins on clinical and biochemical variables in polycystic ovary syndrome. Eur J Contracept Reprod Health Care. 2020;25(3):176–181.
   PubMed Web of Science ®Google Scholar
• Di Carlo C, Gargano V, Sparice S, et al. Effects of an oral contraceptive containing estradiol valerate and dienogest on circulating androgen levels and acne in young patients with PCOS: an observational preliminary study. Gynecol Endocrinol. 2013;29(12):1048–1050.
   PubMed Web of Science ®Google Scholar
• De Leo V, Musacchio MC, Cappelli V, et al. Hormonal contraceptives: pharmacology tailored to women’s health. hum Reprod Update. 2016;22(5):634–646.
   PubMed Web of Science ®Google Scholar
• Murphy A, Cropp CS, Smith BS, et al. Effect of low-dose oral contraceptive on gonadotropins, androgens, and sex hormone binding globulin in nonhirsute women. Fertil Steril. 1990;53(1):35–39.
   PubMed Web of Science ®Google Scholar
• van der Vange N, Blankenstein MA, Kloosterboer HJ, et al. Effects of seven low-dose combined oral contraceptives on sex hormone binding globulin, corticosteroid binding globulin, total and free testosterone. Contraception. 1990;41(4):345–352.
   PubMed Web of Science ®Google Scholar
• Jung-Hoffmann C, Kuhl H. Divergent effects of two low-dose oral contraceptives on sex hormone-binding globulin and free testosterone. Am J Obstet Gynecol. 1987;156(1):199–203. doi: 10.1016/0002-9378(87)90238-9
   PubMed Web of Science ®Google Scholar
• Schneider HP. Androgens and antiandrogens. Ann N Y Acad Sci. 2003;997(1):292–306. doi: 10.1196/annals.1290.033
   PubMedGoogle Scholar
• Kleinstreuer NC, Browne P, Chang X, et al. Evaluation of androgen assay results using a curated Hershberger database. Reprod Toxicol. 2018;81:272–280. doi: 10.1016/j.reprotox.2018.08.017
   PubMed Web of Science ®Google Scholar
• Bosanac SS, Trivedi M, Clark AK, et al. Progestins and acne vulgaris: a review. Dermatol Online J. 2018;24(5):24(5.
   Google Scholar
• Coneac A, Muresan A, Orasan MS. Antiandrogenic therapy with ciproterone acetate in female patients who suffer from both Androgenetic Alopecia and acne vulgaris. Clujul Med. 2014;87(4):226–234. doi: 10.15386/cjmed-386
   PubMedGoogle Scholar
• Palacio-Cardona J, Caicedo Borrero DM. Clinical behavior of a cohort of adult women with facial acne treated with combined oral contraceptive: ethinylestradiol 20 µg/dienogest 2 mg. Int J Womens Health. 2017;9:835–842. doi: 10.2147/IJWH.S139289
   PubMed Web of Science ®Google Scholar
• Rabe T, Kowald A, Ortmann J, et al. Inhibition of skin 5α-reductase by oral contraceptive progestins in vitro. Gynecol Endocrinol. 2000;14(4):223–230.
   PubMed Web of Science ®Google Scholar
• Paris F, Balaguer P, Rimbault F, et al. Molecular action of norgestimate: new developments. Gynecol Endocrinol. 2015;31(6):487–490.
   PubMed Web of Science ®Google Scholar
• Odlind V, Milsom I, Persson I, et al. Can changes in sex hormone binding globulin predict the risk of venous thromboembolism with combined oral contraceptive pills? Acta Obstet Gynecol Scand. 2002;81(6):482–490.
   PubMed Web of Science ®Google Scholar
• Dinh QQ, Sinclair R. Female pattern hair loss: current treatment concepts. Clin Interv Aging. 2007;2(2):189–199.
   PubMed Web of Science ®Google Scholar
• Bitzer J, Römer T, Lopes da Silva Filho A. The use of cyproterone acetate/ethinyl estradiol in hyperandrogenic skin symptoms - a review. Eur J Contracept Reprod Health Care. 2017;22(3):172–182. doi: 10.1080/13625187.2017.1317339
   PubMed Web of Science ®Google Scholar
• Townsend KA, Marlowe KF. Relative safety and efficacy of finasteride for treatment of hirsutism. Ann Pharmacother. 2004;38(6):1070–1073. doi: 10.1345/aph.1D461
   PubMed Web of Science ®Google Scholar
• Simard J, Luthy I, Guay J, et al. Characteristics of interaction of the antiandrogen flutamide with the androgen receptor in various target tissues. Mol Cell Endocrinol. 1986;44(3):261–270.
   PubMed Web of Science ®Google Scholar
• Martin KA, Anderson RR, Chang RJ, et al. Evaluation and Treatment of Hirsutism in Premenopausal Women: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2018;103(4):1233–1257.
   PubMed Web of Science ®Google Scholar
• McCartney CR, Marshall JC. CLINICAL PRACTICE. Polycystic Ovary Syndrome N Engl J Med. 2016;375(1):54–64. doi: 10.1056/NEJMcp1514916
   PubMed Web of Science ®Google Scholar
• Zhao H, Xing C, Zhang J, et al. Comparative efficacy of oral insulin sensitizers metformin, thiazolidinediones, inositol, and berberine in improving endocrine and metabolic profiles in women with PCOS: a network meta-analysis. Reprod Health. 2021;18(1):171.
   PubMed Web of Science ®Google Scholar
• Tso LO, Costello MF, Albuquerque LET, et al. Metformin treatment before and during IVF or ICSI in women with polycystic ovary syndrome. Cochrane Database Syst Rev. 2020;12(12):Cd006105.
   PubMedGoogle Scholar
• Unfer V, Nestler JE, Kamenov ZA, et al. Effects of inositol(s) in women with PCOS: a systematic review of randomized controlled trials. Int J Endocrinol. 2016;2016:1–12. doi: 10.1155/2016/1849162
   Web of Science ®Google Scholar
• Nestler JE, Jakubowicz DJ, de Vargas AF, et al. Insulin stimulates testosterone biosynthesis by human thecal cells from women with polycystic ovary syndrome by activating its own receptor and using inositolglycan mediators as the signal transduction system. J Clin Endocrinol Metab. 1998;83(6):2001–2005.
   PubMed Web of Science ®Google Scholar
• Nestler JE, Unfer V. Reflections on inositol(s) for PCOS therapy: steps toward success. Gynecol Endocrinol. 2015;31(7):501–505. doi: 10.3109/09513590.2015.1054802
   PubMed Web of Science ®Google Scholar
• Dinicola S, Chiu TTY, Unfer V, et al. The rationale of the myo-inositol and D-chiro-inositol combined treatment for polycystic ovary syndrome. J Clin Pharmacol. 2014;54(10):1079–1092.
   PubMed Web of Science ®Google Scholar
• Oguz SH, Yildiz BO. An Update on contraception in polycystic ovary syndrome. Endocrinol Metab. 2021;36(2):296–311. doi: 10.3803/EnM.2021.958
   Google Scholar
• Zimmerman Y, Eijkemans MJC, Coelingh Bennink HJT, et al. The effect of combined oral contraception on testosterone levels in healthy women: a systematic review and meta-analysis. Hum Reprod Update. 2014;20(1):76–105.
   PubMed Web of Science ®Google Scholar
• WHO guidelines approved by the guidelines review committee. In Medical eligibility criteria for contraceptive use. Geneva: World Health Organization; 2015.
   Google Scholar
• Farris M, Bastianelli C, Rosato E, et al. Pharmacodynamics of combined estrogen-progestin oral contraceptives: 2. effects on hemostasis. Expert Rev Clin Pharmacol. 2017;10(10):1129–1144.
   PubMed Web of Science ®Google Scholar
• Li S, Ma L, Song Y, et al. Effects of hormone replacement therapy on glucose and lipid metabolism in peri- and postmenopausal women with a history of menstrual disorders. BMC Endocr Disord. 2021;21(1):121.
   PubMed Web of Science ®Google Scholar
• Çelik Ö, Köse MF. An overview of polycystic ovary syndrome in aging women. J Turk Ger Gynecol Assoc. 2021;22(4):326–333. doi: 10.4274/jtgga.galenos.2021.2021.0077
   PubMed Web of Science ®Google Scholar
• Auer MK, Nordenström A, Lajic S, et al. Congenital adrenal hyperplasia. Lancet. 2023;401(10372):227–244.
   PubMed Web of Science ®Google Scholar
• Speiser PW, Arlt W, Auchus RJ, et al. Congenital adrenal hyperplasia due to steroid 21-hydroxylase deficiency: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2018;103(11):4043–4088.
   PubMed Web of Science ®Google Scholar
• Adriaansen BPH, Schröder MAM, Span PN, et al. Challenges in treatment of patients with non-classic congenital adrenal hyperplasia. Front Endocrinol. 2022;13:1064024. doi: 10.3389/fendo.2022.1064024
   PubMed Web of Science ®Google Scholar
• Pivonello R, Isidori AM, De Martino MC, et al. Complications of Cushing’s syndrome: state of the art. Lancet Diabetes Endocrinol. 2016;4(7):611–629.
   PubMed Web of Science ®Google Scholar
• Hakami OA, Ahmed S, Karavitaki N. Epidemiology and mortality of Cushing’s syndrome. Best Pract Res Clin Endocrinol Metab. 2021;35(1):101521. doi: 10.1016/j.beem.2021.101521
   PubMed Web of Science ®Google Scholar
• Minnetti M, Hasenmajer V, Sbardella E, et al. Susceptibility and characteristics of infections in patients with glucocorticoid excess or insufficiency: the ICARO tool. Eur J Endocrinol. 2022;187(5):719–731.
   PubMed Web of Science ®Google Scholar
• Kaltsas GA, Korbonits M, Isidori AM, et al. How common are polycystic ovaries and the polycystic ovarian syndrome in women with Cushing’s syndrome? Clin Endocrinol (Oxf). 2000;53(4):493–500.
   PubMed Web of Science ®Google Scholar
• Fleseriu M, Auchus R, Bancos I, et al. Consensus on diagnosis and management of Cushing’s disease: a guideline update. Lancet Diabetes Endocrinol. 2021;9(12):847–875.
   PubMed Web of Science ®Google Scholar
• Kaltsas GA, Isidori AM, Kola BP, et al. The value of the low-dose dexamethasone suppression test in the differential diagnosis of hyperandrogenism in women. J Clin Endocrinol Metab. 2003;88(6):2634–2643.
   PubMed Web of Science ®Google Scholar
• Fassnacht M, Dekkers OM, Else T, et al. European Society of Endocrinology clinical Practice guidelines on the management of adrenocortical carcinoma in adults, in collaboration with the European Network for the study of adrenal tumors. Eur J Endocrinol. 2018;179(4):G1–g46.
   PubMed Web of Science ®Google Scholar
• Meczekalski B, Szeliga A, Maciejewska-Jeske M, et al. Hyperthecosis: an underestimated nontumorous cause of hyperandrogenism. Gynecol Endocrinol. 2021;37(8):677–682.
   PubMed Web of Science ®Google Scholar
• Macut D, Ilić D, Jovanović AM, et al. Androgen-Secreting Ovarian Tumors. Front Horm Res. 2019;53:100–107.
   PubMed Web of Science ®Google Scholar
• Rojewska P, Meczekalski B, Bala G, et al. From diagnosis to treatment of androgen-secreting ovarian tumors: a practical approach. Gynecol Endocrinol. 2022;38(7):537–542.
   PubMed Web of Science ®Google Scholar
• Markopoulos MC, Kassi E, Alexandraki KI, et al. Management of endocrine disease: hyperandrogenism after menopause. Eur J Endocrinol. 2015;172(2):R79–91.
   PubMed Web of Science ®Google Scholar
• Yance VRV, Marcondes JAM, Rocha MP, et al. Discriminating between virilizing ovary tumors and ovary hyperthecosis in postmenopausal women: clinical data, hormonal profiles and image studies. Eur J Endocrinol. 2017;177(1):93–102.
   PubMed Web of Science ®Google Scholar
• Melvin A, O’Rahilly S, Savage DB. Genetic syndromes of severe insulin resistance. Curr Opin Genet Dev. 2018;50:60–67. doi: 10.1016/j.gde.2018.02.002
   PubMed Web of Science ®Google Scholar
• Angelidi AM, Filippaios A, Mantzoros CS. Severe insulin resistance syndromes. J Clin Invest. 2021;131(4). doi: 10.1172/JCI142245
   PubMed Web of Science ®Google Scholar
• Bianchi VE, Bresciani E, Meanti R, et al. The role of androgens in women’s health and wellbeing. Pharmacol Res. 2021;171:105758. doi: 10.1016/j.phrs.2021.105758
   PubMed Web of Science ®Google Scholar
• Davis SR, Worsley R, Miller KK, et al. Androgens and female sexual function and dysfunction—findings from the fourth international consultation of sexual medicine. J Sex Med. 2016;13(2):168–178.
   PubMed Web of Science ®Google Scholar
• Kalantaridou SN, Calis KA. Testosterone therapy in premenopausal women. semin Reprod Med. Semin Reprod Med. 2006;24(2):106–114. doi: 10.1055/s-2006-939569
   PubMed Web of Science ®Google Scholar
• Bachmann GA. The hypoandrogenic woman: pathophysiologic overview. Fertil Steril. 2002;77(Suppl 4):S72–6. doi: 10.1016/S0015-0282(02)03003-0
   PubMed Web of Science ®Google Scholar
• Zumoff B, Strain GW, Miller LK, et al. Twenty-four-hour mean plasma testosterone concentration declines with age in normal premenopausal women. J Clin Endocrinol Metab. 1995;80(4):1429–1430.
   PubMed Web of Science ®Google Scholar
• Burger HG, Dudley EC, Cui J, et al. A prospective longitudinal study of serum testosterone, dehydroepiandrosterone sulfate, and sex hormone-binding globulin levels through the menopause transition. J Clin Endocrinol Metab. 2000;85(8):2832–2838.
   PubMed Web of Science ®Google Scholar
• Derman RJ. Effects of sex steroids on women’s health: implications for practitioners. Am J Med. 1995;98(1a):137s–143s. doi: 10.1016/S0002-9343(99)80072-2
   PubMedGoogle Scholar
• Davison SL, Bell R, Donath S, et al. Androgen levels in adult females: changes with age, menopause, and oophorectomy. J Clin Endocrinol Metab. 2005;90(7):3847–3853.
   PubMed Web of Science ®Google Scholar
• Skiba MA, Bell RJ, Islam RM, et al. Androgens during the reproductive years: what is normal for women? J Clin Endocrinol Metab. 2019;104(11):5382–5392.
   PubMed Web of Science ®Google Scholar
• Bachmann G, Bancroft J, Braunstein G, et al. Female androgen insufficiency: the Princeton consensus statement on definition, classification, and assessment. Fertil Steril. 2002;77(4):660–665.
   PubMed Web of Science ®Google Scholar
• Both S, Lew-Starowicz M, Luria M, et al. Hormonal contraception and female sexuality: position statements from the European Society of sexual Medicine (ESSM). J Sex Med. 2019;16(11):1681–1695.
   PubMed Web of Science ®Google Scholar
• Buggio L, Barbara G, Facchin F, et al. The influence of hormonal contraception on depression and female sexuality: a narrative review of the literature. Gynecol Endocrinol. 2022;38(3):193–201.
   PubMed Web of Science ®Google Scholar
• Panzer C, Wise S, Fantini G, et al. Original research—women’s sexual dysfunction: impact of oral contraceptives on sex hormone-binding globulin and androgen levels: a retrospective study in women with sexual dysfunction. J Sex Med. 2006;3(1):104–113.
   PubMed Web of Science ®Google Scholar
• Samsioe G. The role of ERT/HRT. Best Pract Res Clin Obstet Gynaecol. 2002;16(3):371–381. doi: 10.1053/beog.2002.0286
   PubMed Web of Science ®Google Scholar
• Edmunds SE, Stubbs AP, Santos AA, et al. Estrogen and androgen regulation of sex hormone binding globulin secretion by a human liver cell line. J Steroid Biochem Mol Biol. 1990;37(5):733–739.
   PubMed Web of Science ®Google Scholar
• White T, Jain JK, Stanczyk FZ. Effect of oral versus transdermal steroidal contraceptives on androgenic markers. Am J Obstet Gynecol. 2005;192(6):2055–2059. doi: 10.1016/j.ajog.2005.02.067
   PubMed Web of Science ®Google Scholar
• Browne-Martin K, Longcope C. Regulation of sex hormone-binding globulin secretion in human hepatoma G2 cells. Steroids. 2001;66(8):605–607. doi: 10.1016/S0039-128X(01)00094-0
   PubMed Web of Science ®Google Scholar
• Wiegratz I, Kutschera E, Lee JH, et al. Effect of four different oral contraceptives on various sex hormones and serum-binding globulins. Contraception. 2003;67(1):25–32.
   PubMed Web of Science ®Google Scholar
• Arafah BM. Increased need for thyroxine in women with hypothyroidism during estrogen therapy. N Engl J Med. 2001;344(23):1743–1749. doi: 10.1056/NEJM200106073442302
   PubMed Web of Science ®Google Scholar
• Rosen R, Brown C, Heiman J, et al. The female sexual function index (FSFI): a multidimensional self-report instrument for the assessment of female sexual function. J Sex Marital Ther. 2000;26(2):191–208.
   PubMed Web of Science ®Google Scholar
• Davis SR, Baber R, Panay N, et al. Global consensus position statement on the use of testosterone therapy for women. J Clin Endocrinol Metab. 2019;104(10):4660–4666.
   PubMed Web of Science ®Google Scholar
• Maseroli E, Vignozzi L. Are endogenous androgens linked to female sexual function? A systemic review and meta-analysis. J Sex Med. 2022;19(4):553–568. doi: 10.1016/j.jsxm.2022.01.515
   PubMed Web of Science ®Google Scholar
• Laumann EO, Paik A, Rosen RC. Sexual dysfunction in the United States: prevalence and predictors. JAMA. 1999;281(6):537–544. doi: 10.1001/jama.281.6.537
   PubMed Web of Science ®Google Scholar
• Janse F, Tanahatoe SJ, Eijkemans MJC, et al. Testosterone concentrations, using different assays, in different types of ovarian insufficiency: a systematic review and meta-analysis. Hum Reprod Update. 2012;18(4):405–419.
   PubMed Web of Science ®Google Scholar
• van der Stege JG, Groen H, van Zadelhoff SJN, et al. Decreased androgen concentrations and diminished general and sexual well-being in women with premature ovarian failure. Menopause. 2008;15(1):23–31.
   PubMed Web of Science ®Google Scholar
• Gravholt CH, Svenstrup B, Bennett P, et al. Reduced androgen levels in adult turner syndrome: influence of female sex steroids and growth hormone status. Clin Endocrinol (Oxf). 1999;50(6):791–800.
   PubMed Web of Science ®Google Scholar
• Carel JC, Elie C, Ecosse E, et al. Self-esteem and social adjustment in Young women with turner syndrome—influence of pubertal management and sexuality: population-based cohort study. J Clin Endocrinol Metab. 2006;91(8):2972–2979.
   PubMed Web of Science ®Google Scholar
• Davis SR, van der Mooren MJ, van Lunsen RHW, et al. Efficacy and safety of a testosterone patch for the treatment of hypoactive sexual desire disorder in surgically menopausal women: a randomized, placebo-controlled trial. Menopause. 2006;13(3):387–396.
   PubMed Web of Science ®Google Scholar
• Guerrieri GM, Martinez PE, Klug SP, et al. Effects of physiologic testosterone therapy on quality of life, self-esteem, and mood in women with primary ovarian insufficiency. Menopause. 2014;21(9):952–961.
   PubMed Web of Science ®Google Scholar
• Kingsberg SA, Larkin LC, Liu JH. Clinical effects of early or surgical menopause. Obstet Gynecol. 2020;135(4):853–868. doi: 10.1097/AOG.0000000000003729
   PubMed Web of Science ®Google Scholar
• Shifren JL, Braunstein GD, Simon JA, et al. Transdermal testosterone treatment in women with impaired sexual function after oophorectomy. N Engl J Med. 2000;343(10):682–688.
   PubMed Web of Science ®Google Scholar
• Heard-Davison A, Heiman JR, Kuffel S. Genital and subjective measurement of the time course effects of an acute dose of testosterone vs. placebo in postmenopausal women. J Sex Med. 2007;4(1):209–217. doi: 10.1111/j.1743-6109.2006.00406.x
   PubMed Web of Science ®Google Scholar
• Davis SR, Moreau M, Kroll R, et al. Testosterone for low libido in postmenopausal women not taking estrogen. N Engl J Med. 2008;359(19):2005–2017.
   PubMed Web of Science ®Google Scholar
• Panay N, Al-Azzawi F, Bouchard C, et al. Testosterone treatment of HSDD in naturally menopausal women: the ADORE study. Climacteric. 2010;13(2):121–131.
   PubMed Web of Science ®Google Scholar
• Simon J, Braunstein G, Nachtigall L, et al. Testosterone patch increases sexual activity and desire in surgically menopausal women with hypoactive sexual desire disorder. J Clin Endocrinol Metab. 2005;90(9):5226–5233.
   PubMed Web of Science ®Google Scholar
• Shifren JL, Davis SR, Moreau M, et al. Testosterone patch for the treatment of hypoactive sexual desire disorder in naturally menopausal women: results from the INTIMATE NM1 study. Menopause. 2006;13(5):770–779.
   PubMed Web of Science ®Google Scholar
• Clayton AH, Goldstein I, Kim NN, et al. The international Society for the study of women’s sexual health process of care for management of hypoactive sexual desire disorder in women. Mayo Clin Proc. 2018;93(4):467–487.
   PubMed Web of Science ®Google Scholar
• Parish SJ, Simon JA, Davis SR, et al. International Society for the study of women’s sexual health clinical Practice guideline for the use of systemic testosterone for hypoactive sexual desire disorder in women. J Sex Med. 2021;18(5):849–867.
   PubMed Web of Science ®Google Scholar
• Davis SR. Testosterone for women: certainties and uncertainties. Climacteric. 2023;26(1):21–24. doi: 10.1080/13697137.2022.2146492
   PubMed Web of Science ®Google Scholar
• Baber RJ, Panay N, Fenton A. 2016 IMS recommendations on women’s midlife health and menopause hormone therapy. Climacteric. 2016;19(2):109–150. doi: 10.3109/13697137.2015.1129166
   PubMed Web of Science ®Google Scholar
• Islam RM, Bell RJ, Green S, et al. Safety and efficacy of testosterone for women: a systematic review and meta-analysis of randomised controlled trial data. Lancet Diabetes Endocrinol. 2019;7(10):754–766.
   PubMed Web of Science ®Google Scholar
• Achilli C, Pundir J, Ramanathan P, et al. Efficacy and safety of transdermal testosterone in postmenopausal women with hypoactive sexual desire disorder: a systematic review and meta-analysis. Fertil Steril. 2017;107(2):475–482.e15.
   PubMed Web of Science ®Google Scholar
• White WB, Grady D, Giudice LC, et al. A cardiovascular safety study of LibiGel (testosterone gel) in postmenopausal women with elevated cardiovascular risk and hypoactive sexual desire disorder. Am Heart J. 2012;163(1):27–32.
   PubMed Web of Science ®Google Scholar
• Jayasena CN, Alkaabi FM, Liebers CS, et al. A systematic review of randomized controlled trials investigating the efficacy and safety of testosterone therapy for female sexual dysfunction in postmenopausal women. Clin Endocrinol (Oxf). 2019;90(3):391–414.
   PubMed Web of Science ®Google Scholar
• Elraiyah T, Sonbol MB, Wang Z, et al. Clinical review: the benefits and harms of systemic dehydroepiandrosterone (DHEA) in postmenopausal women with normal adrenal function: a systematic review and meta-analysis. J Clin Endocrinol Metab. 2014;99(10):3536–3542.
   PubMed Web of Science ®Google Scholar
• Boyd PR, Mark GJ. Multiple hepatic adenomas and a hepatocellular carcinoma in a man on oral methyl testosterone for eleven years. Cancer. 1977;40(4):1765–1770. doi: 10.1002/1097-0142(197710)40:4<1765:AID-CNCR2820400455>3.0.CO;2-Y
   PubMed Web of Science ®Google Scholar
• Kaaks R, Berrino F, Key T, et al. Serum sex steroids in premenopausal women and breast cancer risk within the European prospective investigation into cancer and nutrition (EPIC). J Natl Cancer Inst. 2005;97(10):755–765.
   PubMed Web of Science ®Google Scholar
• Tuckerman EM, Okon MA, Li T-C, et al. Do androgens have a direct effect on endometrial function? An in vitro study. Fertil Steril. 2000;74(4):771–779.
   PubMed Web of Science ®Google Scholar
• Nachtigall L, Casson P, Lucas J, et al. Safety and tolerability of testosterone patch therapy for up to 4 years in surgically menopausal women receiving oral or transdermal oestrogen. Gynecol Endocrinol. 2011;27(1):39–48.
   PubMed Web of Science ®Google Scholar
• Baldassarre M, Perrone AM, Giannone FA, et al. Androgen receptor expression in the human vagina under different physiological and treatment conditions. Int J Impot Res. 2013;25(1):7–11.
   PubMed Web of Science ®Google Scholar
• Berman JR, Almeida FG, Jolin J, et al. Correlation of androgen receptors, aromatase, and 5-α reductase in the human vagina with menopausal status. Fertil Steril. 2003;79(4):925–931.
   PubMed Web of Science ®Google Scholar
• Raghunandan C, Agrawal S, Dubey P, et al. Original research—Endocrinology: a comparative study of the effects of local estrogen with or without local testosterone on vulvovaginal and sexual dysfunction in postmenopausal women. J Sex Med. 2010;7(3):1284–1290.
   PubMed Web of Science ®Google Scholar
• Witherby S, Johnson J, Demers L, et al. Topical testosterone for breast cancer patients with vaginal atrophy related to aromatase inhibitors: a phase I/II study. Oncology. 2011;16(4):424–431.
   Google Scholar
• Fernandes T, Costa-Paiva LH, Pinto-Neto AM. Efficacy of vaginally applied estrogen, testosterone, or polyacrylic acid on sexual function in postmenopausal women: a randomized controlled trial. J Sex Med. 2014;11(5):1262–1270. doi: 10.1111/jsm.12473
   PubMed Web of Science ®Google Scholar
• Davis SR, Davison SL, Donath S, et al. Circulating androgen levels and self-reported sexual function in women. JAMA. 2005;294(1):91–96.
   PubMed Web of Science ®Google Scholar
• Kritz-Silverstein D, Von Mühlen D, Laughlin GA, et al. Effects of dehydroepiandrosterone supplementation on cognitive function and quality of life: the DHEA and well-ness (DAWN) trial. J Am Geriatr Soc. 2008;56(7):1292–1298.
   PubMed Web of Science ®Google Scholar
• Zimmerman Y, Foidart J-M, Pintiaux A, et al. Restoring testosterone levels by adding dehydroepiandrosterone to a drospirenone containing combined oral contraceptive: II. Clinical Effects Contraception. 2015;91(2):134–142.
   PubMedGoogle Scholar
• Labrie F, Archer D, Bouchard C, et al. Effect of intravaginal dehydroepiandrosterone (prasterone) on libido and sexual dysfunction in postmenopausal women. Menopause. 2009;16(5):923–931.
   PubMed Web of Science ®Google Scholar
• Labrie F, Archer D, Bouchard C, et al. Intravaginal dehydroepiandrosterone (prasterone), a physiological and highly efficient treatment of vaginal atrophy. Menopause. 2009;16(5):907–922.
   PubMed Web of Science ®Google Scholar
• Labrie F, Archer D, Bouchard C, et al. High internal consistency and efficacy of intravaginal DHEA for vaginal atrophy. Gynecol Endocrinol. 2010;26(7):524–532.
   PubMed Web of Science ®Google Scholar
• Labrie F, Archer D, Bouchard C, et al. Serum steroid levels during 12-week intravaginal dehydroepiandrosterone administration. Menopause. 2009;16(5):897–906.
   PubMed Web of Science ®Google Scholar
• Labrie F, Archer D, Bouchard C, et al. Lack of influence of dyspareunia on the beneficial effect of intravaginal prasterone (dehydroepiandrosterone, DHEA) on sexual dysfunction in postmenopausal women. J Sex Med. 2014;11(7):1766–1785.
   PubMed Web of Science ®Google Scholar
• Labrie F, Archer DF, Bouchard C, et al. Intravaginal dehydroepiandrosterone (prasterone), a highly efficient treatment of dyspareunia. Climacteric. 2011;14(2):282–288.
   PubMed Web of Science ®Google Scholar